Genelux (GNLX) Amortizatization of Intangibles (2022 - 2026)
Genelux's (GNLX) quarterly Amortizatization of Intangibles came in at $70000.0 in Q1 2026, down 50.0% year-on-year from $140000.0 in Q1 2025, and up 125.81% quarter-over-quarter from $31000.0 in Q3 2025.
Genelux (GNLX) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Genelux's Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $70000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 50.0% year-over-year to $70000.0 in Q1 2026; TTM through Mar 2026 was $258000.0, a 62.93% decrease from a year earlier, with the FY2023 full-year figure at $62000.0, down 75.97% from the prior year.
- Amortizatization of Intangibles rose to $70000.0 in Q1 2026 per GNLX's latest filing, from $31000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $649000.0 in Q1 2023 and bottomed at -$587000.0 in Q4 2023.
- The 5-year median for Amortizatization of Intangibles is $90000.0 (2022), against an average of $90333.3.
- Biggest YoY gain for Amortizatization of Intangibles was 1224.49% in 2023; the steepest drop was 633.64% in 2023.
- Year by year, Amortizatization of Intangibles stood at $110000.0 in 2022, then sank by 633.64% to -$587000.0 in 2023, then surged by 142.93% to $252000.0 in 2024, then slumped by 87.7% to $31000.0 in 2025, then jumped by 125.81% to $70000.0 in 2026.
- Per Business Quant, the three latest GNLX Amortizatization of Intangibles figures stand at $70000.0 (Q1 2026), $31000.0 (Q3 2025), and $17000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 70,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Dec 31, 2023 | -587,000.00 |
| Dec 31, 2023 | -587,000.00 |
| Mar 31, 2023 | 649,000.00 |
| Mar 31, 2023 | 649,000.00 |
| Dec 31, 2022 | 110,000.00 |
| Dec 31, 2022 | 110,000.00 |